Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis

Abstract

<b>Background:</b> The aims of this study were compare the serum visfatin and resistin levels between endometrialcancer (EC) patients and controls and evaluate their power to predict prognosis. Materials and <br/><b>Methods</b>: Thisprospective study was conducted between March 2013 to June 2014 on the Gynecologic Oncology Departmentof the University of Selcuk, Konya, Turkey. A total of 42 EC patients and 42 controls were included and assessedfor differences in serum visfatin and resistin levels, along with prognostic factors. <br/><b>Results</b>: Endometrial cancerpatients had significantly higher visfatin levels than control s (p: 0.011), associated with deep myometrial invasion(p: 0.019). In contrast the serum level of resistin did not significantly differ between EC patients and controls (p:0.362). However, high resistin level in EC patients was associated with increase lymph node metastasis (p: 0.009).On logistic regression analysis, we found that serum visfatin elevation was associated with risk of myometrialinvasion (OR: 1,091; 95%CI: 1.021- 1.166; p: 0.010) and serum resistin with risk of lymph node metastasis(OR: 1.018; 95%CI: 1.000- 1.035; p: 0.046). For myometrial invasion prediction, a serum visfatin level greaterthan 26.8 ng/mL demonstrated a sensitivity and specificity of 66.6 % and 96.4%, respectively. For lymph nodemetastasis prediction, the best cut-off for serum resistin level was 599ng/mL. A serum resistin level greater thanthis demonstrated a sensitivity and specificity of 87.5% and 77.1%, respectively. <br/><b>Conclusions</b>: Our data suggestthat serum visfatin is elevated in patients with EC and serum visfatin and resistin levels could be used to predictthe risk of advance stage lesions.